

Supplementary material: Assessing the impact of mass testing during a novel infectious disease outbreak: The case of COVID-19

Authors

Yang Ge¹, Brian Kenneth McKay¹, Shengzhi Sun², Feng Zhang³, Andreas Handel¹

Affiliations:

1. Department of Epidemiology and Biostatistics, The University of Georgia, Athens, GA, USA
2. Department of Environmental Health, Boston University School of Public Health, Boston, MA, USA
3. Department of Biostatistics and Data Science, University of Texas Health Science Center at Houston, School of Public Health, Houston, TX, USA

Corresponding author: Yang Ge, Andreas Handel

Corresponding author email: *yang.ge@uga.edu, ahandel@uga.edu*

MSTI and Mortality

It is possible to quantify individual mortality risk similar to transmission risk. A patient staying at home has a mortality risk due to the novel pathogen of $M_H = MP$, where M is the probability of death if a person enters a health care facility under regular circumstances, i.e., when they feel bad enough to seek medical care. P is the probability that they are in fact infected with the novel pathogen.

For individuals who go through an MSTI, there are two possible scenarios. If the symptomatic individual is infected with the novel pathogen (probability P), we assume that they are correctly identified and placed under isolation and treatment, where they have reduced mortality risk, namely $M_I P$. If they do not have the infection, there is a chance they get infected during testing, and the same reasoning as for transmission risk applies, leading to the total mortality risk under MSTI of $M_S = M_I P + MF(1 - P)$. In analogy to the transmission risk ratio, we can define a mortality risk ratio as $MRR = M_S/M_H$. Under the optimistic assumption that diagnosis will lead to no mortality, i.e. $M_I = 0$, MRR takes the same form as TRR shown in the main text. Scenarios with $M_I > 0$ are explored below.

Estimating F and P for a few pathogens

The MSTI strategy we discuss here depends on values for the proportion, P , of individuals that show a set of symptoms who are infected with the novel pathogen, and the risk of infection due to being at a testing site, F . Precise estimates for either of those quantities are unlikely to be available for any setting. However, if the right data is collected, it is possible to get decent estimates. Unfortunately, since MSTI has not been formally evaluated previously, the right kind of data is not available. As an alternative, we searched the literature and tried to find reports that had some data that would allow us to estimate F and P for a few pathogens. The following

sections explain how we obtained those estimates. Due to the strong limitations with the data, these estimates should be considered very approximate and uncertain.

Ebola

One study (1) reports a scenario where 464 of 724 patients (64%) suspected to have Ebola virus disease (EVD) were found to have EVD. A similar fraction was reported for a different setting in another study (2), with 276 of 433 suspected patients (64%) having EVD. In (3), the fraction is $108/154 = 70\%$. while (4) report $822/2362=35\%$. Based on these reports, we obtain an estimate for P in the range of 0.35-0.7.

To estimate F , we use data from (5), which reports that among a cohort of 543 patients who initially did not have EVD and were discharged, 18 later likely developed EDV. It is unclear if they got infected in the facility, but an upper bound would be $18/543 = 0.03$. In a similar study (6) found $9/138=0.07$ as an upper bound. This leads to an estimate for F in the range of 0.03-0.07.

Measles

In (7), the authors analyzed four sets of data to determine confirmed measles cases among those having a clinical diagnosis and found those to be $77/128=0.60$, $1/26=0.04$, $1/93=0.01$, $74/213=0.35$. This leads to an estimate for P covering a wide range of 0.01-0.6.

To estimate F , we use data from (8), which reports a case where a single visit to an emergency department resulted in 12 cases. They do not report the number of exposed persons. If we make a guess of around 100, we obtain a risk of infection of $12/100=0.12$. Similarly, (9) report 4 cases caused by an ED visit of an infected patient. Again using a total size of around 100 for those exposed we get $4/100=0.04$. This leads to an estimate for F in the range of 0.04-0.12.

COVID-19

We consider data from two different settings, Washington State in the U.S. and Wuhan in China.

Washington State, U.S.

For an estimate of P , we used daily testing data in Washington state between March 6 and March 27, 2020 (10). During that time, the fraction of positive tests ranged from 6.5-19%. We use those values as a proxy for the fraction of individuals with general respiratory symptoms who have COVID-19. This leads to an estimate for P in the range 0.065-0.19.

To estimate F , we consider data King County Life Care Center in Kirkland, WA (11). While the details of who infected whom are not fully clear yet, it is likely that one index patient infected the majority of others in that facility. Cases associated with this outbreak were 81/130 residents and 34/170 staff members. It is unclear how many of these cases are caused by the index patient. If we assume all cases were caused by the index, we obtain an upper bound of $115/300 = 38\%$. As a lower bound, we assume that only a tenth of the cases were caused by the index. This leads to an estimate for F in the range of 0.038-0.38.

Wuhan, China

Notes of a press conference held by National Health Commission of the People's Republic of China show there were 10261 total fever clinic visits in Wuhan on Jan 27, 2020 (12), with 315 confirmed cases reported next day (13). Similarly, 12512 and 12568 total fever clinic visits occurred on Feb 3 and 4 (14), with 1967 and 1766 confirmed cases reported the next day (15,16). If we use the reported fever visits as indication of the total number of individuals showing respiratory symptoms and the next day reported cases as the number among those individuals who are infected with COVID-19, we obtain as estimates for P the values $315/10261$, $1967/12512$ and $1766/12568$, which leads to an estimated range for P of 0.03-0.16.

To estimate F , we use data from (17), which reports that one patient infected 4 hospitalized patients in the same ward. We do not know the number of exposed persons in this ward. If we take a range of 10 - 50, this would lead to risk of infection from $4/10$ - $4/50$, thus average F in the range of 0.08 - 0.4.

Scenarios with non-perfect isolation

In the main text, we considered the optimistic case where isolation following testing led to no further transmission and no mortality. Here, we explore how results change if instead isolation only reduced those quantities by some amount. The general expressions for transmission risk ratio (TRR) and mortality risk ratio (MRR) are given by $TRR = T_S/T_H = R_I/R + (1 - P)F/P$ and $MRR = M_S/M_H = M_I/M_0 + (1 - P)F/P$. The figure explores scenarios ranging from isolation having very little effect on transmission and mortality risk and only reducing them by 10% (i.e. $R_I = 0.9R$ and $M_I = 0.9M$) up to a reduction of 90% (i.e. $R_I = 0.1R$ and $M_I = 0.1M$). As expected, a smaller reduction in infection and mortality risk shrinks the range for which MSTI is a beneficial strategy.




Figure 1: Simulation of TRR and MRR in scenarios; A: $R_I = 0.9R$, B: $R_I = 0.5R$, C: $R_I = 0.1R$,

D: $M_I = 0.9M$, E: $M_I = 0.5M$, F: $M_I = 0.1M$

An explicit equation for the probability of infection

The probability of infection, F , is expected to increase as the proportion of individuals infected with the novel pathogen increases and will saturate at some maximum value. This can be described by a simple function $F = P/(K + P)$, where K describes the strength of the infection control at the testing site. For small K , F will eventually approach 1. For infection control strength of $K = 1$, the maximum risk of transmission, (if prevalence were to be $P = 1$) would be $F = 0.5$.




Figure 2: MSTI associated infection risk, F , as a function of novel pathogen prevalence among symptomatic, P , given by $F = P/(K + P)$ for different values of K .

If we use $F = P/(K + P)$ in our TRR and MRR equations, we find $TRR = T_S/T_H = R_I/R + (1 - P)/(K + P)$ and $MRR = M_S/M_H = M_I/M_0 + (1 - P)/(K + P)$. With the assumption of perfect isolation ($R_I = M_I = 0$), this becomes $TRR = MRR = (1 - P)/(K + P)$.

For MSTI to be useful, we need to have $TRR = MRR < 1$, and thus $(K + P) > (1 - P)$ or $K > 1 - 2P$. This shows that infection control needs to be strongest at $K \geq 1$ for low prevalence, and once $P \geq 0.5$, even zero infection control will make MSTI beneficial. This corresponds to the main text discussion of keeping $F < P$ for low prevalence, while the value of F does not matter once prevalence reaches 0.5.

Note that the infection control parameter K in our model is in arbitrary units without a clear way to connect and measure it for any specific setting. If any 2 of K , F and P are known, the third quantity can be estimated. It is more likely that data can be obtained for infection risk F , instead of K , which is why we focused on F in the main text.

References

1. Lado M, Walker NF, Baker P, Haroon S, Brown CS, Youkee D, et al. Clinical features of patients isolated for suspected ebola virus disease at connaught hospital, freetown, sierra leone: A retrospective cohort study. *The Lancet infectious diseases*. 2015;15(9):1024–33.
2. Vogt F, Fitzpatrick G, Patten G, Bergh R van den, Stinson K, Pandolfi L, et al. Assessment of the msf triage system, separating patients into different wards pending ebola virus laboratory confirmation, kailahun, sierra leone, july to september 2014. *Eurosurveillance*. 2015;20(50):30097.
3. Yan T, Mu J, Qin E, Wang Y, Liu L, Wu D, et al. Clinical characteristics of 154 patients suspected of having ebola virus disease in the ebola holding center of jui government hospital in sierra leone during the 2014 ebola outbreak. *European journal of clinical microbiology & infectious diseases*. 2015;34(10):2089–95.
4. Ingelbeen B, Bah EI, Decroo T, Balde I, Nordenstedt H, Griensven J van, et al. Mortality among pcr negative admitted ebola suspects during the 2014/15 outbreak in conakry, guinea: A retrospective cohort study. *PloS one*. 2017;12(6).
5. Arkell P, Youkee D, Brown CS, Kamara A, Kamara TB, Johnson O, et al. Quantifying the risk of nosocomial infection within ebola holding units: A retrospective cohort study of negative patients discharged from five ebola holding units in western area, sierra leone. *Tropical Medicine & International Health*. 2017;22(1):32–40.
6. Fitzpatrick G, Vogt F, Gbabei OM, Black B, Santantonio M, Folkesson E, et al. Describing readmissions to an ebola case management centre (cmc), sierra leone, 2014. *Eurosurveillance*. 2014;19(40):20924.

7. Hutchins SS, Amler R, Maes EF, Grabowsky M, Bromberg K, Glasglow V, et al. Evaluation of the measles clinical case definition. *The Journal of infectious diseases*. 2004;189(Supplement_1):S153–9.
8. Porretta A, Quattrone F, Aquino F, Pieve G, Bruni B, Gemignani G, et al. A nosocomial measles outbreak in italy, february-april 2017. *Eurosurveillance*. 2017;22(33).
9. Chen SY, Anderson S, Kutty PK, Lugo F, McDonald M, Rota PA, et al. Health care-associated measles outbreak in the united states after an importation: Challenges and economic impact. *Journal of Infectious Diseases*. 2011 Apr;203(11):1517–25.
10. Project TCT. The COVID Tracking Project [Internet]. 2020 [cited 2020 Mar 28]. Available from: <https://covidtracking.com>
11. McMichael TM. COVID-19 in a Long-Term Care Facility King County, Washington, February 27-March 9, 2020. *MMWR Morbidity and Mortality Weekly Report*. 2020;69.
12. National Health Commission. Transcript of the press conference on January 27, 2020- National Health Commission of the People’s Republic of China [Internet]. National Health Commission of the People’s Republic of China, editor. [cited 2020 Feb 5]. Available from: <http://www.nhc.gov.cn/xcs/s3574/202001/50050057b6fe4a2b90763d95c4273ceb.shtml>
13. Provincial Health Committee. Transcript of epidemic situation of new coronavirus infection in hubei on January 28, 2020 [Internet]. Hubei Provincial Health Committee, editor. 2020 [cited 2020 Feb 5]. Available from: http://wjw.hubei.gov.cn/fbjd/dtyw/202001/t20200129_2015921.shtml
14. National Health Commission. Transcript of the press conference on February 4, 2020- National Health Commission of the People’s Republic of China [Internet]. National Health

Commission of the People's Republic of China, editor. 2020 [cited 2020 Feb 5]. Available from:
<http://www.nhc.gov.cn/wjw/xwdt/202002/35990d56cfcb43f4a70d7f9703b113c0.shtml>

15. Provincial Health Committee. Transcript of epidemic situation of new coronavirus infection in hubei on February 3, 2020 [Internet]. Hubei Provincial Health Committee, editor. 2020 [cited 2020 Feb 5]. Available from:

http://wjw.hubei.gov.cn/fbjd/dtyw/202002/t20200204_2018742.shtml

16. Provincial Health Committee. Transcript of epidemic situation of new coronavirus infection in hubei on February 4, 2020 [Internet]. Hubei Provincial Health Committee, editor. 2020 [cited 2020 Feb 5]. Available from:

http://wjw.hubei.gov.cn/fbjd/dtyw/202002/t20200205_2019293.shtml

17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusInfected pneumonia in wuhan, china. JAMA. 2020 Feb;